现有病毒疫苗用于防治新冠肺炎的可行性分析

doi:10.3976/j.issn.1002-4026.2020.02.001

山东科学 ›› 2020, Vol. 33 ›› Issue (2): 1-11.doi: 10.3976/j.issn.1002-4026.2020.02.001

• 新冠肺炎防控 • 下一篇

现有病毒疫苗用于防治新冠肺炎的可行性分析

孙晨^1a,1b，何秋霞^1a,1b，高燕^1a,1b，张磊²，李宁^1a,1b，刘可春^1a,1b*

1.齐鲁工业大学（山东省科学院）山东省科学院生物研究所，a. 山东省人类疾病斑马鱼模型与药物筛选工程技术研究中心；b. 山东省生物检测技术工程实验室，山东济南 250103; 2.澳大利亚联邦药物管理局生物部，澳大利亚西蒙斯顿 2609

收稿日期:2020-02-25 出版日期:2020-04-20 发布日期:2020-03-30
通信作者: 刘可春(1964—)，男，博士，研究员，研究方向为药物筛选。Tel: 15020009568 E-mail:hliukch@sdas.org
作者简介:孙晨（1985—），女，博士，助理研究员，研究方向为药物筛选。E-mail: mornings0123@163.com 何秋霞（1980—），共同第一作者，女，博士，副研究员，研究方向为药物筛选。E-mail: heqiuxia8008@163.com
基金资助:
国家重点研发计划（2018YFC1707300）；山东省科学院国际科技合作项目（2019GHZD10，2019GHZD13）

Exploring preventive measures for COVID-19 based on the existing virus vaccines

SUN Chen^1a,1b, HE Qiu-xia^1a,1b, GAO Yan^1a,1b, ZHANG Lei², LI Ning^1a,1b, LIU Ke-chun^1a,1b*

1. a. Engineering Research Center of Zebrafish Models for Human Diseases and Drug Screening of Shandong Province;b.Shandong Provincial Engineering Laboratory for Biological Testing Technology,Biology Institute, Qilu University of Technology (Shandong Academy of Sciences)，Jinan 250103, China; 2. Biological Section, Therapeutic Goods Administration, Symonston 2609, Australia

Received:2020-02-25 Online:2020-04-20 Published:2020-03-30

摘要/Abstract

摘要： 新冠肺炎的爆发严重危害人类健康和公共卫生安全，已引起全球范围内的高度关注。预防病毒性疾病最有效的措施是接种疫苗，但是目前还没有专门针对新型冠状病毒的疫苗。考虑到疫情的严重性，对同为RNA病毒的流感病毒、其他冠状病毒相关疫苗的研究进行了综述，并通过对这些病毒氨基酸水平的序列比对发现，新冠病毒的棘突糖蛋白与H1N1、H3N2、B型Victoria系和B型Yamagata系流感病毒的血凝素糖蛋白之间具有一定的相似性。由于血凝素糖蛋白是目前商用流感疫苗的主要作用靶点，因此推测，现有季节性商用流感疫苗在新冠肺炎的防控方面可能也具有一定的应用潜能。除此之外，由于新冠病毒与SARS冠状病毒的棘突糖蛋白和核蛋白之间均具有高度的相似性，而SARS冠状病毒疫苗又主要从上述两种蛋白研制而来，因此建议在短期内，可以将目前正在研制的SARS冠状病毒疫苗作为新冠病毒特效疫苗的替代物来使用。

关键词: 新冠肺炎, 疫苗, 流感病毒, SARS病毒, 冠状病毒

Abstract: The outbreak of COVID-19 is seriously endangering human and public health. It has caused great concern all around the world. The most effective measure to prevent viral diseases is vaccination. But there has no specific vaccine been approved for this disease yet. Considering the serious effect of the epidemic,this article reviewed the related vaccines research on influenza viruses and coronaviruses, and their amino acid sequences were compared. The results show that there are some similarity between the spike of 2019-nCoV and hemagglutinin from influenza A virus and influenza B virus. The hemagglutinin of influenza is the major targets of current commercial sensonal influenza vaccines which imply that vaccines might be beneficial for prevention of COVID-19. Besides that, because of the high similarity between spike and nucleocapsid of SARS-CoV and 2019-nCoV, we believe that the SARS-CoV vaccine may be an alternative that can be used for the control of COVID-19 in the short term.

Key words: COVID-19, vaccine, influenza virus, SARS-CoV, corvonavirus

中图分类号:

R183.3

孙晨, 何秋霞, 高燕, 张磊, 李宁, 刘可春. 现有病毒疫苗用于防治新冠肺炎的可行性分析[J]. 山东科学, 2020, 33(2): 1-11.

SUN Chen, HE Qiu-xia, GAO Yan, ZHANG Lei, LI Ning, LIU Ke-chun. Exploring preventive measures for COVID-19 based on the existing virus vaccines[J]. Shandong Science, 2020, 33(2): 1-11.

参考文献 56

1	CHEN N S, ZHOU M, DONG X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. The Lancet, 2020, 395(10223): 507-513. doi: 10.1016/S0140-6736(20)30211-7
2	中国新闻网. 黑龙江省3例新冠肺炎死亡患者均为患有慢性疾病老年人[EB/OL]. (2020-02-09)[2020-02-25].http://www.chinanews.com/sh/2020/02-09/9084552.
3	国家卫生健康委员会. 截至2月24日24时新型冠状病毒肺炎疫情最新情况[EB/OL]. (2020-02-25)[2020-02-25].http://www.nhc.gov.cn/xcs/yqtb/202002/67e6c59a84bd4f07b6ca4a4c5ffabb79.shtml.
4	国家卫生健康委办公厅. 新型冠状病毒肺炎诊断方案（试行第六版）[EB/OL]. (2020-02-19)[2020-02-25].http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf.
5	北青网. 新冠肺炎康复者血浆治疗超10人临床症状明显好转[EB/OL]. (2020-02-14)[2020-02-25].https://www.xianjichina.com/news/details_185590.html.
6	PALESE P. Influenza: old and new threats[J]. Nature Medicine, 2004, 10(12): 82-87. doi: 10.1038/nm1141
7	IULIANO A D , ROGUSKI K M , CHANG H H , et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study[J]. The Lancet, 2017, 391(10127): 1285-1300. DOI:10.1016/S0140-6736(17)33293-2. doi: 10.1016/S0140-6736(17)33293-2
8	TRUCCHI C, PAGANINO C, AMICIZIA D, et al. Universal influenza virus vaccines: what needs to happen next[J]. Expert Opinion on Biological Therapy, 2019, 19(7): 671-683. doi: 10.1080/14712598.2019.1604671
9	高福, 施一. 中国流感病毒结构生物学研究:40年回眸[J]. 生物化学与生物物理进展, 2014(10): 1029-1033.
10	DU L Y, ZHOU Y S, JIANG S B. Research and development of universal influenza vaccines[J]. Microbes and Infection, 2010, 12(4): 280-286. doi: 10.1016/j.micinf.2010.01.001
11	FOUCHIER R A M, MUNSTER V, WALLENSTEN A, et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls[J]. Journal of Virology, 2005, 79(5): 814-2822. doi: 10.1128/jvi.79.5.2814-2822.2005
12	SKEHEL J J, WILEY D C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin[J]. Annual Review of Biochemistry, 2000, 69(1): 531-569. doi: 10.1146/annurev.biochem.69.1.531
13	FONI E, CHIAPPONI C, BAIONI L, et al. Influenza D in Italy: towards a better understanding of an emerging viral infection in swine[J]. Scientific Reports, 2017, 7(1): 11660. doi: 10.1038/s41598-017-12012-3
14	中国疾病预防控制中心. 中国流感疫苗预防接种技术指南（2019—2020）[EB/OL].(2019-10-16)[2020-02-25].http://www.chinacdc.cn/jkzt/crb/bl/lxxgm/jszl_2251/201910/t20191016_206297.html.
15	HANNOUN C. The evolving history of influenza viruses and influenza vaccines[J]. Expert Review of Vaccines, 2013, 12(9): 1085-1094. doi: 10.1586/14760584.2013.824709
16	BERLANDA SCORZA F, TSVETNITSKY V, DONNELLY J J. Universal influenza vaccines: shifting to better vaccines[J]. Vaccine, 2016, 34(26): 2926-2933. doi: 10.1016/j.vaccine.2016.03.085
17	AMBROSE C S, LEVIN M J. The rationale for quadrivalent influenza vaccines[J]. Human Vaccines & Immunotherapeutics, 2012, 8(1): 81-88. doi: 10.4161/hv.8.1.17623
18	JAZAYERI S D, POH C L. Development of universal influenza vaccines targeting conserved viral proteins[J]. Vaccines, 2019, 7(4): 169. doi: 10.3390/vaccines7040169
19	KUBO H, YAMADA Y K, TAGUCHI F. Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein[J]. Journal of Virology, 1994, 68(9): 5403-5410. doi: 10.1128/jvi.68.9.5403-5410.1994
20	MCBRIDE R, VAN ZYL M, FIELDING B. The coronavirus nucleocapsid is a multifunctional protein[J]. Viruses, 2014, 6(8): 2991-3018. doi: 10.3390/v6082991
21	HAMRE D, PROCKNOW J J. A new virus isolated from the human respiratory tract[J]. Experimental Biology and Medicine, 1966, 121(1): 190-193. doi: 10.3181/00379727-121-30734
22	HENDLEY J O, FISHBURNE H B,Jr GWALTNEY J M. Coronavirus infections in working adults eight-year study with 229 E and OC 43[J]. The American Review of Respiratory Disease, 1972, 105(5): 805-811. doi: 10.1164/arrd.1972.105.5.805
23	der VAN H L, PYRC K, JEBBINK M F, et al. Identification of a new human coronavirus[J]. Nature Medicine, 2004, 10(4): 368-373. doi: 10.1038/nm1024
24	FRIEDMAN N, ALTER H, HINDIYEH M, et al. Human coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU[J]. Viruses, 2018, 10(10): 515. doi: 10.3390/v10100515
25	孟娟丽, 沈晓玲, 谭文杰. SARS冠状病毒病毒样颗粒疫苗的研究进展[J]. 生物技术通讯, 2014,25(2): 268-271. doi: 10.3969/j.issn.1009-0002.2014.02.027
26	B-EZ-SANTOS Y M, ST J S E, MESECAR A D. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds[J]. Antiviral Research, 2015, 115: 21-38. doi: 10.1016/j.antiviral.2014.12.015
27	LUIS E, MARTA LDD, ENRIQUE A, et al. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease[J]. Virus Research, 2008, 133(1): 45-62. doi: 10.1016/j.virusres.2007.01.021
28	广东省防治非典型肺炎科技攻关疫苗专题组.SARS 冠状病毒灭活疫苗研究初报[J].广东医学,2003,24(增刊1):129-130. DOI：10.13820/j.cnki.gdyx.2003.s1.051. doi: 10.13820/j.cnki.gdyx.2003.s1.051
29	曾玉红. SARS 疫苗研究进展[J]. 国际免疫学杂志,2007, 30( 4) : 266-269. doi: 10.3760/cma.j.issn.1673-4394.2007.04.018
30	MARSHALL E, ENSERINK M. Medicine. Cautionurged on SARS vaccines[J]. Science, 2004, 303(5660): 944-946. doi: 10.1126/science.303.5660.944
31	RACHEL L G, ERIC F D, RALPH S B. A decade after SARS: strategies for controlling emerging coronaviruses[J]. Nature Reviews Microbiology, 2013, 11(12): 836-848. doi: 10.1038/nrmicro3143
32	LI F, LI W, FARZAN M et al. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor[J]. Science, 2005, 309(5742): 1864-1868. doi: 10.1126/science.1116480
33	GUPTA V, TABIIN T M, SUN K, et al. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens[J]. Virology, 2006, 347(1): 127-139. doi: 10.1016/j.virol.2005.11.042
34	FETT C, DEDIEGO M L, REGLANAVA J A, et al. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein[J]. Journal of Virology, 2013, 87(12): 6551-6559. doi: 10.1128/JVI.00087-13
35	GRAHAM R L, BECKER M M, ECKERLE L D, et al. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease[J]. Nature Medicine, 2012, 18(12): 1820-1826. doi: 10.1038/nm.2972
36	BISHT H, ROBERTS A, VOGEL L, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice[J]. Proceedings of the National Academy of Sciences, 2004, 101(17): 6641-6646. doi: 10.1073/pnas.0401939101
37	BUCHHOLZ U J, BUKREYEV A, YANG L, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity[J]. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101(26): 9804-9809. doi: 10.1073/pnas.0403492101
38	FABER M, LAMIRANDE E W, ROBERTS A, et al. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies[J]. Journal of General Virology, 2005, 86(5): 1435-1440. doi: 10.1099/vir.0.80844-0
39	KAPADIA S U, ROSE J K, LAMIRANDE E, et al. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine[J]. Virology, 2005, 340(2): 174-182. doi: 10.1016/j.virol.2005.06.016
40	LIU S J, LENG C H, LIEN S P, et al. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates[J]. Vaccine, 2006, 24(16): 3100-3108. doi: 10.1016/j.vaccine.2006.01.058
41	CHEN Z, ZHANG L, QIN C, et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region[J]. Journal of Virology, 2005, 79(5): 2678-2688. doi: 10.1128/JVI.79.5.2678-2688.2005
42	WOO P C Y, LAU S K P, TSOIH W , et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus[J]. Vaccine, 2005, 23(42): 4959-4968. doi: 10.1016/j.vaccine.2005.05.023
43	SHI S Q, PENG J P, LI Y C, et al. The of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization[J]. Molecular Immunology, 2006, 43(11): 1791-1798. doi: 10.1016/j.molimm.2005.11.005
44	HUI D S, AZHAR E I, KIM Y J, et al. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission[J]. The Lancet Infectious Diseases, 2018, 18(8): e217-e227. doi: 10.1016/S1473-3099(18)30127-0
45	World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV)[EB/OL].[2020-02-25].https://www.who.int/emergencies/mers-cov/en/.
46	CHAFEKAR A, FIELDING B C. MERS-CoV: understanding the latest human coronavirus threat[J]. Viruses, 2018, 10(2): E93. DOI:10.3390/v10020093. doi: 10.3390/v10020093
47	ZHOU Y S,JIANG S B,DU L Y.Prospects for a MERS-CoV spike vaccine[J].Expert Review of Vaccines, 2018, 17(8): 677-686. doi: 10.1080/14760584.2018.1506702
48	LEE J Y, BAE S, MYOUNG J. Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-β promoter activation: its implication for vaccine design[J]. Journal of Microbiology, 2019, 57(9): 803-811. doi: 10.1007/s12275-019-9272-7
49	CHAN J W, KOK K H, ZHU Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan[J]. Emerging Microbes Infections, 2020, 9(1): 221-236. doi: 10.1080/22221751.2020.1719902
50	CERAOLO C, GIORGI F M. Genomic variance of the 2019-nCoV coronavirus[EB/OL]. (2020-02-06)[2020-02-25].https://doi.org/10.1002/jmv.25700. doi: doi.org/10.1002/jmv.25700
51	BENVENUTO D, GIOVANNETTI M, CICCOZZI A, et al. The 2019-new coronavirus epidemic: Evidence for virus evolution[EB/OL].(2020-01-29)[2020-02-25].https://doi.org/10.1002/jmv.25688. doi: 10.1002/jmv.25688
52	WRAPP D, WANG N, CORBETT K S, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[EB/OL]. (2020-02-15)[2020-02-25]. https://doi.org/ 10.1126/science.abb2507. doi: 10.1126/science.abb2507
53	陈晶, 金焱, 马可欣. 非典时期我们没有用上疫苗,这次能吗？[EB/OL]. (2020-02-11)[2020-02-25]. https://xw.qq.com/cmsid/20200210A0PSHN00.
54	医诺医学. 好消息！Vir 鉴定出两种可与新冠肺炎病毒结合的单克隆抗体[EB/OL]. (2020-02-13)[2020-02-25]. http://www.ulabmed.com/content-154-5248-1.html.
55	医麦客. 新冠疫苗：Moderna完成临床级产品的生产分装，即将投入临床 [EB/OL]. (2020-02-12)[2020-02-25]. https://xueqiu.com/5603603160/141073949.
56	周烨真, 张世豪, 陈嘉仪, 等.新型冠状病毒SARS-CoV-2的变异和进化分析J . 南方医科大学学报，2020，40(2): 152-158. doi: 10.12122/j.issn.1673-4254.2020.02.02

[1]	朱洁, 王征, 梁艳妮. 基于网络药理学探究小青龙汤治疗新型冠状病毒肺炎的作用机制[J]. 山东科学, 2023, 36(3): 10-17.
[2]	杜海涛, 王平, 李娜, 丁洁, 张敬, 袁成民, 孙铁锋, 韩莉, 张忠法. 基于网络药理学与分子对接的新冠肺炎三焦疫毒寒湿症用药机理研究 [J]. 山东科学, 2021, 34(1): 1-9.
[3]	刘京华, 谭旺晓, 王斯维, 王雨, 王小莹. 基于网络药理学探讨葶苈大枣泻肺汤治疗新冠肺炎的作用机制[J]. 山东科学, 2020, 33(5): 1-13.
[4]	汪宗清, 聂红科, 李青璇, 王兴强, 汤小虎. 基于网络药理学探讨黄芪六君子汤治疗新冠肺炎恢复期的作用机制[J]. 山东科学, 2020, 33(5): 14-26.
[5]	孙慧囡, 高广恒, 刘庆艾, 马耀宏, 李静, 史建国. 血乳酸生物传感器在新冠肺炎诊疗中的应用探讨[J]. 山东科学, 2020, 33(3): 1-6.
[6]	孙强, 边昕. 基于太阳光紫外线和风环境模拟的武汉雷神山医院防疫工作规划分析响应[J]. 山东科学, 2020, 33(3): 7-17.
[7]	徐瑞东, 田明伟. 一次性医用防护服研究进展[J]. 山东科学, 2020, 33(3): 18-27.
[8]	王凤霞, 张云, 刘可春. 基于《伤寒论》理法方药理论浅谈新冠肺炎防控策略[J]. 山东科学, 2020, 33(2): 12-16.
[9]	牛凌, 景元旺, 罗磷. 智慧化交通在疫情联防联控中的应用探讨[J]. 山东科学, 2020, 33(2): 17-21.

现有病毒疫苗用于防治新冠肺炎的可行性分析

Exploring preventive measures for COVID-19 based on the existing virus vaccines

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献 56

相关文章 9

Metrics

本文评价

推荐阅读 0